Rapamycin est immunosuppressive medicamento, anti-cancer et anti-canus
Product Detail
| Nomen | RAPAMYCIN |
| Cas numerum | 53123-88-9 |
| MOLECULA | C51h79no13 |
| Pondus | 914.19 |
| Einecs numerum | 610-965-5 |
| PRAETERITUS | 799,83 ° C (praedicta) |
| Densitas | 1.0352 |
| Repono condicionem | Signatum in sicco, copia in freezer, sub -20 ° C |
| Forma | Pulverem |
| Colo | Alba |
| Stipare | PE lapides sacculi + Aluminium |
Synonyma
(XXII) CMLXXXIX, 23,27-epoxy-3h-Pyrido (2,1-c) (1,4) oxazacyencentriacontina; NSSC-(XXIIVI) LXXX; Rapa; Rapamune, Rapamycin; Rapamycin, Rapamune;
Pharmacological effectus
Descriptio
Rapamycin est macrolide antibiotic, quod est structuram similar adcofol (fk506), sed habet valde diversis immunosuppressive mechanism. FK506 inhibits in T fluprum G0 Phase in G1 tempus, cum Rapa cuneos signaling per diversis cytokine receptores et cuneos ex G1 phase T-Lymphocytes et alias cellulis ex G1 phase ad s phase, comparari et calcium, Rapa potest, ut obstructionum calcium, et calcium, raa potest angustos, comparari et calcium, raaps potest angustos calcium, et calcium-lymphocytes, et B. University of Chicago Medical Inquisitores uti commercially available oris Rapamycin tabulae plus grapefruit sucus tractare melanoma, a communi malignus tumor morbo in Europa et Civitatum Foederatis Medicamenta, ita extemplo superessendam aegris tempore. Studiis ostensum est quod Rapamycin facile decompositis per enzymes post intrantes digestive tractu et grapefruit sucus habet magna moles FuranocoMarin, quae potest inhibere perniciosum effectum digestivorum tractus enzymes in rapamycin. Potest amplio bioavailability de rapamycin. Dicitur quod prima Batavi Doctores inventa quod grapefruit sucus habet effectum improvidus in oris effusio de Shannming et nunc doctores in Europae et American regionibus applicantur ad Rapamycin Praeparata.
In annis, studiis invenerunt quod in scopum de rapamycin (mtor) est intracellular kinase et deprauationem eius conduction via potest inducere varietate morborum. Ut targeted inhibitor in Mtor, Rapamycin potest tractare tumores propinqua ad hunc viam, inter Renum Cancer, Lymphoma, pulmone cancer, iecoris cancer, pectus cancer, neuroendocrinis cancer et Cancer. Praesertim in curatio duorum rara morbo, Lam (lymphangiomyomatosis) et TSC (tuberosa), quod effectus est manifestius, et Lam et TSC potest etiam in tumore morbos.
Parte effectus
Rapamycin (Rapa) habet similes latus effectus ad FK506. In multitudine orci iudiciis, ejus latus effectus inventa est ut dose-dependens et reversible, et Rapa at therapeoutios doses non inventum esse significant nephrotoxicity et non est inventa est significant Nephrotoxicity et non invenitur Hyperplasia. Pelagus toxicus et latus effectus includit: capitis, nausea, vertigine, naribus, et iuncturam dolor. Laboratory abnormalities includit: Thombocytopenia, Leukopenia, humilis Hemoglobin, hypertriglyceridemia, hypercholesterolemia, hypertriglycemia, elevatum iecoris enzymes (Sgot, HyelMalemia, Hypomagnesemia, etc. Cum Rapa Administration, et causa inferioris Plasma Phosphate levels est cogitatio est longum differentur phosphate excretion ab transplantatione renibus per Rapa-secundum immunosuppressive Lorem. Sicut alias immunosuppressants, Rapa habet augeri forte infectio, cum nuntiavit tendentia ad augendam Pneumonia maxime, sed eventum alia opportunistic infectiones non significantly diversis a CSA.
